DK3292105T3 - Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) - Google Patents

Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) Download PDF

Info

Publication number: DK3292105T3
Authority: DK; Denmark
Prior art keywords: pyrazold; flap; inhibitors; activating protein; derivatives used
Prior art date: 2015-05-04

Application number

DK16720116T

Other languages

English (en)

Inventor

Johan Olof Broddefalk

Hans Fredrik Emtenäs

Kenneth Lars Granberg

Malin Anita Lemurell

Daniel Tor Pettersen

Alleyn Thomas Plowright

Lars Johan Andreas Ulander

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-05-04

Filing date

2016-05-03

Publication date

2019-12-09

2016-05-03 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2019-12-09 Application granted granted Critical

2019-12-09 Publication of DK3292105T3 publication Critical patent/DK3292105T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/38—Nitrogen atoms
- C07D231/40—Acylated on said nitrogen atom
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
- C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
- C07D231/50—Acylated on said nitrogen atom
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Pulmonology (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Gastroenterology & Hepatology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

DK16720116T 2015-05-04 2016-05-03 Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap) DK3292105T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562156424P	2015-05-04	2015-05-04
PCT/EP2016/059848 WO2016177703A1 (en)	2015-05-04	2016-05-03	Pyrazole derivatives useful as 5-lipoxygenase activating protein (flap) inhibitors

Publications (1)

Publication Number	Publication Date
DK3292105T3 true DK3292105T3 (da)	2019-12-09

Family

ID=55910253

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK19199606.5T DK3670499T3 (da)	2015-05-04	2016-05-03	Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)
DK16720116T DK3292105T3 (da)	2015-05-04	2016-05-03	Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK19199606.5T DK3670499T3 (da)	2015-05-04	2016-05-03	Pyrazolderivater, der er anvendelige som inhibitorer af 5-lipoxygenase-aktiverende protein (flap)

Country Status (38)

Country	Link
US (6)	US10183947B2 (da)
EP (2)	EP3670499B1 (da)
JP (1)	JP6564062B2 (da)
KR (1)	KR102623474B1 (da)
CN (1)	CN107646036B (da)
AR (1)	AR104512A1 (da)
AU (1)	AU2016258874B2 (da)
BR (1)	BR112017022757B1 (da)
CA (1)	CA2983668C (da)
CL (1)	CL2017002660A1 (da)
CO (1)	CO2017011506A2 (da)
CR (1)	CR20170513A (da)
CY (2)	CY1122689T1 (da)
DK (2)	DK3670499T3 (da)
DO (1)	DOP2017000244A (da)
EA (1)	EA032221B1 (da)
ES (2)	ES2902139T3 (da)
GT (1)	GT201700220A (da)
HR (2)	HRP20211993T1 (da)
HU (2)	HUE047445T2 (da)
IL (1)	IL255069B (da)
LT (1)	LT3670499T (da)
ME (1)	ME03663B (da)
MX (1)	MX372755B (da)
MY (1)	MY186647A (da)
PE (1)	PE20180247A1 (da)
PH (1)	PH12017502112B1 (da)
PL (2)	PL3292105T3 (da)
PT (2)	PT3670499T (da)
RS (2)	RS59671B1 (da)
SG (1)	SG11201708558RA (da)
SI (2)	SI3670499T1 (da)
SM (2)	SMT202100722T1 (da)
SV (1)	SV2017005549A (da)
TN (1)	TN2017000458A1 (da)
TW (1)	TWI718146B (da)
WO (1)	WO2016177703A1 (da)
ZA (1)	ZA201708189B (da)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EA032221B1 (ru)	2015-05-04	2019-04-30	Астразенека Аб	Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)
CN109890385B (zh) *	2016-10-28	2022-08-02	阿斯利康(瑞典)有限公司	(1r,2r)-2-[4-(3-甲基-1h-吡唑-5-基)苯甲酰基]-n-(4-氧代-4,5,6,7-四氢吡唑并[1,5-a]吡嗪-3-基)环己烷甲酰胺的结晶形式
GB201905721D0 (en)	2019-04-24	2019-06-05	Univ Dundee	Compounds
CN110169969B (zh) *	2019-06-28	2022-05-27	南京医科大学	Mk571在制备预防和治疗心脏病药物中应用
CN111084775A (zh) *	2020-02-17	2020-05-01	牡丹江医学院	一种用于治疗癫痫的药物组合物
CN111419800B (zh) *	2020-04-23	2021-03-19	温州医科大学附属第二医院、温州医科大学附属育英儿童医院	用于治疗红斑狼疮的药物制剂及其制备方法
CN111643498B (zh) *	2020-07-20	2021-05-07	黑龙江中医药大学	一种治疗肾结石的药物组合物及其用途
CN111714499B (zh) *	2020-07-27	2021-05-11	黑龙江中医药大学	一种用于治疗多囊卵巢综合征的药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AP9400632A0 (en)	1993-04-29	1995-10-07	Zeneca Ltd	Ether derivatives.
US5773422A (en)	1996-01-29	1998-06-30	Komer; Gene	Avermectin formulation
EP1670804A2 (en) *	2003-09-10	2006-06-21	GPC Biotech AG	Heterobicyclic compounds as pharmaceutically active agents
GB2431927B (en) *	2005-11-04	2010-03-17	Amira Pharmaceuticals Inc	5-Lipoxygenase-activating protein (FLAP) inhibitors
TW200815351A (en) *	2006-05-02	2008-04-01	Astrazeneca Ab	Novel compounds
WO2008097930A1 (en) *	2007-02-05	2008-08-14	Amira Pharmaceuticals, Inc.	Reverse indoles as 5-lipoxygenase-activating protein (flap) inhibitors
GB0702456D0 (en) *	2007-02-08	2007-03-21	Astrazeneca Ab	New combination
JP2010524944A (ja) *	2007-04-20	2010-07-22	シェーリングコーポレイション	テトラヒドロピリド［４，３−ｄ］ピリミジノン誘導体およびそれらの使用方法
BRPI0811204A8 (pt) *	2007-05-10	2015-09-22	Bristol Myers Squibb Co	Tetra-hidroibenzo-1,4-diazepinas substituídas por arila e heteroarila e uso das mesmas para bloquear a recaptação de norepinefrina, dopamina e serotonina
EP2207547A4 (en) *	2007-10-05	2010-11-17	Amira Pharmaceuticals Inc	PROTEIN INHIBITORS THAT ACTIVATE 5-LIPOXYGENASE
EA032221B1 (ru) *	2015-05-04	2019-04-30	Астразенека Аб	Производные пиразола, пригодные в качестве ингибиторов белка, активирующего 5-липоксигеназу (flap)

2016
- 2016-05-03 EA EA201792341A patent/EA032221B1/ru not_active IP Right Cessation
- 2016-05-03 SI SI201631428T patent/SI3670499T1/sl unknown
- 2016-05-03 PT PT191996065T patent/PT3670499T/pt unknown
- 2016-05-03 HR HRP20211993TT patent/HRP20211993T1/hr unknown
- 2016-05-03 TN TNP/2017/000458A patent/TN2017000458A1/en unknown
- 2016-05-03 JP JP2017555792A patent/JP6564062B2/ja active Active
- 2016-05-03 EP EP19199606.5A patent/EP3670499B1/en active Active
- 2016-05-03 RS RS20191604A patent/RS59671B1/sr unknown
- 2016-05-03 DK DK19199606.5T patent/DK3670499T3/da active
- 2016-05-03 HR HRP20192172TT patent/HRP20192172T1/hr unknown
- 2016-05-03 SG SG11201708558RA patent/SG11201708558RA/en unknown
- 2016-05-03 PL PL16720116T patent/PL3292105T3/pl unknown
- 2016-05-03 RS RS20211559A patent/RS62729B1/sr unknown
- 2016-05-03 DK DK16720116T patent/DK3292105T3/da active
- 2016-05-03 US US15/571,291 patent/US10183947B2/en active Active
- 2016-05-03 CN CN201680029387.0A patent/CN107646036B/zh active Active
- 2016-05-03 HU HUE16720116A patent/HUE047445T2/hu unknown
- 2016-05-03 PL PL19199606T patent/PL3670499T3/pl unknown
- 2016-05-03 SM SM20210722T patent/SMT202100722T1/it unknown
- 2016-05-03 MY MYPI2017704101A patent/MY186647A/en unknown
- 2016-05-03 HU HUE19199606A patent/HUE056875T2/hu unknown
- 2016-05-03 CR CR20170513A patent/CR20170513A/es unknown
- 2016-05-03 ME MEP-2019-358A patent/ME03663B/me unknown
- 2016-05-03 KR KR1020177034920A patent/KR102623474B1/ko active Active
- 2016-05-03 ES ES19199606T patent/ES2902139T3/es active Active
- 2016-05-03 PT PT167201169T patent/PT3292105T/pt unknown
- 2016-05-03 CA CA2983668A patent/CA2983668C/en active Active
- 2016-05-03 SI SI201630537T patent/SI3292105T1/sl unknown
- 2016-05-03 EP EP16720116.9A patent/EP3292105B1/en active Active
- 2016-05-03 AR ARP160101257A patent/AR104512A1/es active IP Right Grant
- 2016-05-03 MX MX2017013571A patent/MX372755B/es active IP Right Grant
- 2016-05-03 ES ES16720116T patent/ES2760466T3/es active Active
- 2016-05-03 SM SM20190691T patent/SMT201900691T1/it unknown
- 2016-05-03 WO PCT/EP2016/059848 patent/WO2016177703A1/en not_active Ceased
- 2016-05-03 LT LTEP19199606.5T patent/LT3670499T/lt unknown
- 2016-05-03 TW TW105113757A patent/TWI718146B/zh active
- 2016-05-03 AU AU2016258874A patent/AU2016258874B2/en active Active
- 2016-05-03 PE PE2017002308A patent/PE20180247A1/es unknown
- 2016-05-03 BR BR112017022757-6A patent/BR112017022757B1/pt active IP Right Grant
2017
- 2017-10-16 IL IL255069A patent/IL255069B/en active IP Right Grant
- 2017-10-18 GT GT201700220A patent/GT201700220A/es unknown
- 2017-10-19 CL CL2017002660A patent/CL2017002660A1/es unknown
- 2017-10-20 DO DO2017000244A patent/DOP2017000244A/es unknown
- 2017-10-20 SV SV2017005549A patent/SV2017005549A/es unknown
- 2017-11-09 CO CONC2017/0011506A patent/CO2017011506A2/es unknown
- 2017-11-21 PH PH12017502112A patent/PH12017502112B1/en unknown
- 2017-12-01 ZA ZA2017/08189A patent/ZA201708189B/en unknown
2018
- 2018-11-20 US US16/196,217 patent/US10508119B2/en active Active
2019
- 2019-10-30 US US16/668,743 patent/US11001589B2/en active Active
- 2019-12-03 CY CY20191101268T patent/CY1122689T1/el unknown
2021
- 2021-04-22 US US17/237,656 patent/US11691978B2/en active Active
- 2021-12-23 CY CY20211101130T patent/CY1125179T1/el unknown
2023
- 2023-02-27 US US18/174,832 patent/US12024523B2/en active Active
2024
- 2024-05-21 US US18/670,264 patent/US20240317767A1/en active Pending

Also Published As

Publication number	Publication date
SMT202100722T1 (it)	2022-01-10
EP3292105A1 (en)	2018-03-14
CN107646036B (zh)	2020-05-19
CR20170513A (es)	2018-02-13
US20240317767A1 (en)	2024-09-26
CY1125179T1 (el)	2023-03-24
PT3292105T (pt)	2019-12-13
MY186647A (en)	2021-08-03
PH12017502112B1 (en)	2021-07-02
EA201792341A1 (ru)	2018-05-31
SI3292105T1 (sl)	2020-01-31
LT3670499T (lt)	2021-12-27
PL3670499T3 (pl)	2022-02-14
CN107646036A (zh)	2018-01-30
IL255069B (en)	2019-12-31
JP6564062B2 (ja)	2019-08-21
EP3292105B1 (en)	2019-10-02
US20230219967A1 (en)	2023-07-13
PT3670499T (pt)	2021-12-24
AU2016258874A1 (en)	2017-12-14
DK3670499T3 (da)	2022-01-03
HUE056875T2 (hu)	2022-03-28
EP3670499B1 (en)	2021-09-29
US12024523B2 (en)	2024-07-02
CA2983668A1 (en)	2016-11-10
JP2018514535A (ja)	2018-06-07
KR20180002784A (ko)	2018-01-08
TW201713625A (zh)	2017-04-16
NZ737672A (en)	2020-11-27
CO2017011506A2 (es)	2018-01-31
DOP2017000244A (es)	2017-11-15
HK1245255A1 (en)	2018-08-24
HRP20192172T1 (hr)	2020-02-21
PL3292105T3 (pl)	2020-04-30
EP3670499A1 (en)	2020-06-24
TN2017000458A1 (en)	2019-04-12
HRP20211993T1 (hr)	2022-04-01
KR102623474B1 (ko)	2024-01-09
MX372755B (es)	2020-06-29
MX2017013571A (es)	2018-02-26
ES2760466T3 (es)	2020-05-14
US20210355127A1 (en)	2021-11-18
BR112017022757A2 (pt)	2018-07-17
US10508119B2 (en)	2019-12-17
RS59671B1 (sr)	2020-01-31
ME03663B (me)	2020-07-20
US11001589B2 (en)	2021-05-11
US20180237439A1 (en)	2018-08-23
SG11201708558RA (en)	2017-11-29
BR112017022757B1 (pt)	2023-02-23
PH12017502112A1 (en)	2018-05-07
SI3670499T1 (sl)	2022-02-28
US11691978B2 (en)	2023-07-04
GT201700220A (es)	2018-12-19
SV2017005549A (es)	2018-03-12
ZA201708189B (en)	2018-11-28
SMT201900691T1 (it)	2020-01-14
IL255069A0 (en)	2017-12-31
RS62729B1 (sr)	2022-01-31
HUE047445T2 (hu)	2020-04-28
AU2016258874B2 (en)	2020-04-30
CA2983668C (en)	2023-06-27
US10183947B2 (en)	2019-01-22
US20200157113A1 (en)	2020-05-21
TWI718146B (zh)	2021-02-11
US20190084991A1 (en)	2019-03-21
PE20180247A1 (es)	2018-02-02
ES2902139T3 (es)	2022-03-25
EA032221B1 (ru)	2019-04-30
CL2017002660A1 (es)	2018-04-13
CY1122689T1 (el)	2021-03-12
WO2016177703A1 (en)	2016-11-10
AR104512A1 (es)	2017-07-26

Publication	Publication Date	Title
DK3302448T3 (da)	2024-02-05	Erstattede heterocyclylafledninger som cdk-inhibitore
DK3442980T3 (da)	2021-08-30	Heterocykliske forbindelser som ret-kinase-hæmmere
DK3464271T3 (da)	2020-06-15	Pyrazolderivater som plasma-kallikreininhibitorer
LT3464272T (lt)	2022-03-10	Nauji heterocikliniai dariniai, naudingi kaip shp2 inhibitoriai
DK3377488T3 (da)	2022-10-03	Heterocykliske forbindelser som immunomodulatorer
DK3472167T3 (da)	2022-09-05	Heterocykliske forbindelser som immunomodulatorer
DK3371190T3 (da)	2022-05-23	Heterocykliske forbindelser som pi3k-gamma-inhibitorer
DK3768674T3 (da)	2024-02-19	Aminopyrimidinderivater som ctps1-hæmmere
DK3356345T3 (da)	2024-02-12	Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer
DK3294738T3 (da)	2021-06-28	Mono- og disubstituerede indolderivater som inhibitorer af replikation af denguevirus
DK3461821T3 (da)	2020-08-17	Indolcarboxamidforbindelser, der er brugbar som kinasehæmmere
DK3119762T3 (da)	2021-08-30	Benzimidazol-derivater som erbb-tyrosin-kinase-inhibitorer til behandlingen af kræft
DK3319956T3 (da)	2021-03-29	Substituerede oxopyridinderivater
DK3567037T3 (da)	2021-02-08	N-((het)arylmethyl)-heteroaryl-carboxamidforbindelser som plasmakallikreininhibitorer
DK3094631T3 (da)	2019-05-06	Pyrimidinyloxybenzenderivater som herbicider
DK3348556T3 (da)	2020-08-03	Heteroarylamider som hæmmere af proteinaggregering
DK3313832T3 (da)	2021-04-19	3-tetrazolyl-benzen-1,2-disulfonamidderivater som metallo-beta- lactamase-hæmmere
DK3271349T3 (da)	2019-08-05	Benzimidazolederivater som bromodomain-inhibitorer
DK3204378T3 (da)	2019-10-21	N-pyridinylacetamidderivater som hæmmere af wnt-signaleringsbanen
DK3436435T3 (da)	2021-08-09	Substituerede indolderivater som inhibitorer af replikation af denguevirus
DK3601225T3 (da)	2021-08-16	Substituerede indolinderivater som inhibitorer af denguevirus-replikation
DK3350163T3 (da)	2020-03-16	Mono- eller disubstituerede indolderivater som hæmmere af denguevirusreplikation
DK3244886T3 (da)	2022-01-17	Indolderivater som inhibitorer af dengue virus-replikation
PL3457851T3 (pl)	2022-03-14	Pochodne sobetiromu
DK3116475T3 (da)	2020-12-07	Dopa-decarboxylasehæmmersammensætninger